The drug is available as a weight-loss medication under the brand name Wegovy and will now also be sold directly to diabetes ...

Viking Therapeutics, Inc.'s obesity drug VK2735 results reveal no clear edge over leading competitors. Click for why this ...

Diabetic medicine Ozempic now approved by Health Canada to reduce the risk of further kidney decline among patients with Type ...

What To Know: Under the agreement, all strengths of the medications will now be available to eligible self-paying patients at $499 per month through GoodRx's platform.

Viking Therapeutics stock tumbled after the drugmaker released study results of its experimental weight-loss pill.

Viking Therapeutics shares plunged 40% after trial data for its obesity pill, VK2735, revealed high dropout rates due to side ...

Health Canada has approved Ozempic to reduce the risk of further kidney decline among patients with Type 2 diabetes, which has raised questions.

Eli Lilly and Novo Nordisk are expected to price their new obesity pills in line with existing injections, as analysts cite ...

VK2735 met its primary endpoint but failed to outdo competitors Novo Nordisk and Eli Lilly in terms of body weight loss.

Viking Therapeutics (NASDAQ:VKTX) fell ~43% as analysts reacted to mid-stage trial data for its oral GLP-1/GIP dual receptor ...

Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.

Viking Therapeutics' new GLP-1 weight loss pill, VK2735, helped patients shed 12.2% of their body weight in 13 weeks. The ...